Supplementary

Characteristics	Conventional MIE	Phase 1	P value	Phase 2	P value	Phase 3	P value	Phase 4	P value
Age	61.12±8.37	62.17±7.08	0.604	60.09±6.42	0.609	63.09±8.74	0.312	61.65±8.03	0.801
BMI(kg/m ²)	22.46±3.57	23.19±2.90	0.394	22.80±2.53	0.682	22.88±4.81	0.647	23.60±3.32	0.199
Female/male	15/34	4/19	0.269	3/19	0.152	6/26	0.234	3/20	0.148
Diabetes	4 (8.2%)	1 (4.3%)	1.000	1 (4.5%)	1.000	2 (6.3%)	1.000	1 (4.3%)	1.000
hypertension	9 (18.4%)	6 (26.1%)	0.452	5 (22.7%)	0.669	11 (34.4%)	0.102	4 (17.4%)	1.000
Tumor location Upper Middle and Lower	4 (8.2%) 45 (91.8%)	5 (21.7%) 18 (78.3%)	0.133	2 (9.1%) 20 (90.9%)	0.897	6 (18.8%) 26 (81.3%)	0.182	0 (0.0%) 23 (100.0%)	0.299
Surgical approach Ivor Lewis McKeown	12 (24.5%) 37 (75.5%)	0 (0.0%) 23 (100%)	0.007	3 (13.6%) 19 (86.4%)	0.363	14 (43.8%) 18 (56.3%)	0.070	14 (60.9%) 9 (39.1%)	0.003
Histology SCC Other	45 (91.8%) 4 (8.2%)	21 (91.3%) 2 (8.7%)	1.000	20 (90.9%) 2 (9.1%)	1.000	27 (84.4%) 5 (15.6%)	0.471	20 (87.0%) 3 (13.0%)	0.673
RLN-LN	2.24±2.33	2.00±2.15	0.672	2.77±2.22	0.374	1.81±2.18	0.405	2.22±2.70	0.965
Thoracic LNs	9.96±5.20	8.22±3.24	0.088	13.05±5.64	0.027	8.66±3.61	0.221	10.61±5.28	0.625
Abdomen LNs	7.86±5.48	10.61±8.34	0.159	10.86±6.24	0.044	10.06±6.83	0.113	11.35±6.23	0.019
Total LN	17.86±7.49	18.83±9.13	0.635	23.91±7.10	0.002	18.72±8.25	0.628	21.96±7.85	0.036
T stage T0-T2 T3-T4a	21 (42.9%) 28 (57.1%)	12 (52.2%) 11 (47.8%)	0.459	9 (40.9%) 13 (59.1%)	0.878	12 (37.5%) 20 (62.5%)	0.631	12 (52.2%) 11 (47.8%)	0.459
N stage N0-N1 N2-N3	39 (80.0%) 10 (20.0%)	19 (82.6%) 4 (17.4%)	1.000	18 (81.8%) 4 (18.2%)	1.000	23 (71.9%) 9 (28.1%)	0.423	18 (78.3%) 5 (21.7%)	0.897
TNM Stage 0-II III-IVa	28 (57.1%) 21 (42.9%)	12 (52.2%) 11 (47.8%)	0.692	12 (54.5%) 10 (45.5%)	0.838	17 (53.1%) 15 (46.9%)	0.722	16 (70.0%) 7 (30.0%)	0.313

Note: BMI= body mass index, SCC= squamous cell carcinoma, LN= lymph node, MIE= minimal invasive esophagectomy, RAMIE= robotassisted minimal invasive esophagectomy, RLN-LN= recurrent laryngeal nerve lymph node